公开(公告)号：EP4365295A1

公开(公告)日：2024-05-08

申请号：EP22832556.9

申请日：2022-03-31

申请人： Aichi Prefecture

发明人： KAGOYA, Yuki ,  YOSHIKAWA, Toshiaki

IPC分类号： C12N15/62 ,  A61K35/15 ,  A61K35/17 ,  A61P35/00 ,  C07K14/715 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/10 ,  C12N15/12 ,  C12N15/63

CPC分类号： A61P35/00 ,  C07K14/435 ,  C07K14/715 ,  C07K19/00 ,  C12N5/06 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  A61K39/4631 ,  A61K39/4611 ,  A61K39/464419 ,  A61K39/464412 ,  A61K39/464468 ,  A61K2239/4820230501 ,  A61K39/464471

摘要： To achieve both of improvement of therapeutic efficacy and reduction of side effects in adoptive immunotherapy, the present invention provides a novel technique for enhancing functions such as proliferation ability and imparting an activity of capturing cytokines which may cause side effects in immune cells for use in the adoptive immunotherapy. Provided is a chimeric cytokine receptor comprising a ligand-binding region at the N-terminal side and a T-cell activating region at the C-terminal side, wherein: said ligand-binding region consists of a cytokine-binding region of a cytokine receptor, said T-cell activating region comprises the transmembrane domain and the intracellular domain of an IL-7 (Interleukin-7) receptor α chain, and said transmembrane domain has an insertion of any one selected from the group consisting of (a) the amino acid sequence of SEQ ID NO: 2 between position 243 and position 244 in the amino acid sequence of SEQ ID NO: 1, (b) the amino acid sequence of SEQ ID NO: 3 between position 241 and position 242 in the amino acid sequence of SEQ ID NO: 1, (c) the amino acid sequence of SEQ ID NO: 4 between position 244 and position 245 in the amino acid sequence of SEQ ID NO: 1, (d) the amino acid sequence of SEQ ID NO: 5 between position 244 and position 245 in the amino acid sequence of SEQ ID NO: 1, and (e) the amino acid sequence of SEQ ID NO: 6 between position 246 and position 247 in the amino acid sequence of SEQ ID NO: 1.